The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

The Men Behind Wellbeing — Chapter Nine

We followed Stephen Ray’s science backwards through patents, Lydac Neuroscience and ultimately the company’s insolvency. Now the investigation returns to where it began: Wellbeing International Foundation. If the Cell-Free Therapy being promoted today developed from the same scientific lineage as the microvesicle technology once assigned to Lydac, where did Wellbeing obtain the rights—and what does it actually own?

For the last several chapters, this investigation has travelled backwards.

We started with Wellbeing International Foundation.

We followed Stephen Ray.

Ray led us to patents.

The patents led us to Lydac Neuroscience Limited.

Lydac led us to Andrew Chancellor.

And Chancellor's involvement with Lydac eventually led us into the insolvency of the biotechnology company historically associated with Ray's microvesicle intellectual property.

But Chapter Eight brought us to an important point.

We now need to turn around.

Because this investigation was never really about a failed company called Lydac Neuroscience.

It is about Wellbeing International Foundation today.

And after everything we have uncovered, there is a question that prospective patients—and particularly prospective investors—should be asking:

What intellectual property does Wellbeing actually own?

Start With Wellbeing's Own Description of Its Technology

We don't need to speculate about how Wellbeing describes Cell-Free Therapy.

Its current website tells us.

Wellbeing says a patient's blood is taken, white blood cells are isolated and placed under controlled conditions, and the resulting preparation contains:

extracellular vesicles;

growth factors;

and:

cytokines.

The material is then returned to the same patient intravenously.

Wellbeing describes the treatment as both autologous and cell-free. (Wellbeing International Foundation)

Extracellular vesicles are not a minor footnote in this description.

They are central to Wellbeing's explanation of how CFT works.

On its science page, Wellbeing describes extracellular vesicles as membrane-bound packages carrying proteins, RNA and other biological material, and presents them as part of the delivery system involved in cellular signalling. (Wellbeing International Foundation)

Keep that terminology in mind.

Because now we go backwards again.

What Did Stephen Ray Patent?

The international patent application WO2009087361A1 is titled:

Microvesicles.

Its priority history begins on 4 January 2008.

Stephen Ray is named as inventor.

And the original assignee is:

Lydac Neuroscience Ltd. (Google Patents)

The corresponding European patent, EP2240189B1, describes methods for producing microvesicles, particularly immunologically matched autologous microvesicles, with potential therapeutic, cosmetic and other applications.

Again:

Inventor — Stephen Ray.

Original Assignee — Lydac Neuroscience Ltd. (Google Patents)

Now place the two descriptions beside one another.

The historical technology:

autologous microvesicles.

The present Wellbeing treatment:

autologous biological material containing extracellular vesicles.

Same scientist.

Related scientific field.

And terminology that is sufficiently close to demand investigation.

But This Is Where We Must Be Careful

This investigation has not established that Wellbeing's current Cell-Free Therapy is EP2240189B1.

That would be too simplistic.

Microvesicles sit within the broader field of extracellular-vesicle biology, but scientific terminology, isolation techniques, conditioning methods and manufacturing processes have developed substantially since 2008.

CFT could incorporate later discoveries.

It could involve processes not claimed by the old patent.

It could depend upon proprietary laboratory know-how.

There could be subsequent intellectual property.

And the old patent itself is currently shown as not in force in Google Patents, whose database also cautions that its legal-status and assignee information should not be treated as definitive legal conclusions. (Google Patents)

So the responsible question is not:

“Is Wellbeing using Lydac's patent?”

We don't yet know.

The question is:

“What is the scientific and legal relationship between Ray's Lydac-era microvesicle technology and Wellbeing's present Cell-Free Therapy?”

That is much harder to dismiss.

Wellbeing Itself Connects Its Present Science to Stephen Ray's Earlier Work

There is another reason this deserves investigation.

Wellbeing doesn't present Stephen Ray as somebody who recently joined an unrelated project.

Its current website describes him as its Senior Scientific Consultant and credits him with more than 30 years of academic and commercial research experience in cell therapy. (Wellbeing International Foundation)

More strikingly, a Wellbeing-branded testimonials website explicitly traces the organisation's origins to Ray's earlier research.

It says the Foundation's journey began with Ray's research into the proposition that the regenerative effects attributed to stem cells were associated with their secretions, including microvesicles and exosomes, now commonly discussed within the broader extracellular-vesicle field. (Wellbeing International Foundation)

That matters enormously.

Because it strengthens the reason for examining the old patent history.

The scientific lineage is not merely something critics are trying to construct.

Wellbeing's own public material presents a historical narrative connecting its current work with Ray's earlier research.

So now we need to follow the legal lineage as carefully as the scientific one.

Science Can Travel. Ownership Doesn't Travel Automatically.

This distinction is fundamental.

Stephen Ray invented technology.

That doesn't necessarily mean Stephen Ray personally owned the patent rights.

The patent records identify Lydac Neuroscience Limited as the original assignee. (Google Patents)

Likewise, Ray subsequently working with Wellbeing does not automatically transfer intellectual property once owned by Lydac to Wellbeing.

Andrew Chancellor later directing Lydac does not transfer those rights either.

And Ray and Chancellor subsequently appearing together at Wellbeing certainly does not, by itself, create a legal chain of ownership.

Intellectual property has to be dealt with through legal mechanisms.

Assignment.

Sale.

Licence.

Acquisition.

Expiration.

Abandonment.

Or the creation of genuinely new intellectual property.

So which happened here?

The Patent Database Still Says Lydac

This is where things become particularly interesting.

The current Google Patents entry for European patent EP2240189B1 displays:

Original Assignee: Lydac Neuroscience Ltd

and:

Current Assignee: Lydac Neuroscience Ltd. (Google Patents)

But there is a major caveat.

Google explicitly warns that listed assignee information may be inaccurate and that it has not performed a legal analysis.

The same page lists the patent's status as:

Not-in-force.

So we cannot take that database entry and declare that Lydac remained the legally enforceable owner of every relevant right until dissolution.

But something else is equally important.

Our investigation has not yet located a public assignment in this European record transferring this patent to Wellbeing International Foundation.

That doesn't prove no such commercial arrangement exists.

But it means we haven't found the bridge.

And Lydac No Longer Exists

This makes the question considerably sharper.

Lydac entered administration in December 2018.

It subsequently entered creditors' voluntary liquidation.

And ultimately the company was dissolved.

If commercially important intellectual property remained inside Lydac during that process, it had to be dealt with somehow.

Perhaps administrators sold it.

Perhaps rights had already moved.

Perhaps they expired.

Perhaps they were abandoned.

Perhaps the valuable part of the technology was actually know-how rather than patent rights.

Perhaps later research rendered the original patent commercially irrelevant.

All are possible.

But somewhere there should be an explanation.

The Science Was Already Being Used Before Lydac Collapsed

Here the chronology becomes even more interesting.

Wellbeing currently publishes a case study concerning Paul Cook.

According to Wellbeing's own account, Max Lewinsohn introduced Cook to Stephen Ray in November 2017.

Wellbeing says Cook then began a cell-free treatment programme involving extracellular vesicles derived from his own cells. (Wellbeing International Foundation)

Look carefully at that date.

November 2017.

Lydac did not enter administration until:

December 2018.

That means Wellbeing's own account places Ray-associated autologous extracellular-vesicle treatment activity before Lydac entered administration.

This does not establish that Lydac owned the treatment.

It does not establish that the 2017 treatment fell within Lydac's patent claims.

But it gives us a much narrower period to investigate.

By 2017, according to Wellbeing's own account, Ray was already involved in administering or supporting a cell-free programme based on autologous extracellular vesicles.

At the same time, Lydac—the company historically associated with Ray's microvesicle intellectual property—still existed.

That overlap deserves serious examination.

So Who Owned What in 2017?

This may now be one of the most important questions in the investigation.

When that treatment programme was reportedly operating in 2017:

Who owned the relevant technology?

Was it Lydac?

Stephen Ray?

Wellbeing?

Another company?

Was there a licence?

Was the process sufficiently different from the patented invention that no licence was required?

Were the old patents already irrelevant?

Or was the commercial technology based upon scientific know-how that was never contained within the patent?

Again, there may be entirely legitimate answers.

But the chronology means the question can no longer be pushed entirely into the post-insolvency period.

Then Lydac Collapses

One year later, administrators arrived.

This brings Chapter Eight straight back into the story.

If Lydac still held relevant intellectual property in December 2018, the administrators should have considered it as part of the company's assets.

If it had already left the company, we need to know when.

If it was licensed, the licence may itself have had value.

If the patents had little commercial relevance by then, we need to understand why.

And if the actual commercial value lay not in the patents but in confidential protocols or scientific know-how, we need to understand who controlled that.

This is why the insolvency documents matter.

They may tell us whether there really is a missing asset—or whether the answer is something completely different.

Then Comes the Investment Round

And this is where the investigation stops being purely historical.

Wellbeing announced in March 2026 that it had closed the opening tranche of its current capital round.

It says that round remains open.

According to Wellbeing, the money supports continuing research, expansion of its clinical-relationship network in the United States and Europe, documentation work and operational capacity.

Wellbeing also says it has historically been funded through a combination of:

private investment;

patient revenue;

and:

selective philanthropy. (Wellbeing International Foundation)

That means intellectual-property ownership isn't merely interesting.

For an investor, it could be fundamental.

What Is an Investor Actually Investing In?

Imagine approaching this without knowing any of the history we have uncovered.

You are considering investing in a biotechnology organisation.

You are shown a therapy based around sophisticated regenerative biology.

You are told about decades of scientific experience.

You are shown extracellular-vesicle science.

You see a substantial research library.

You see patient case studies.

You see international expansion.

And you are being invited into a capital round.

A reasonable investor should ask:

What proprietary scientific asset does the organisation actually control?

That question should be answered before discussing future valuations.

Owning the Brand Is Not the Same as Owning the Technology

A company can own a brand.

A website.

Marketing material.

Patient relationships.

Data.

Contracts.

Laboratory relationships.

Protocols.

Trade secrets.

Patents.

Patent licences.

Those are all different assets.

So when we ask whether Wellbeing “owns the science”, we need to be precise.

Science itself is not generally something one company simply owns.

Specific inventions can be patented.

Know-how can be protected contractually.

Processes can be kept as trade secrets.

Data can have commercial value.

Licences can grant exclusive or non-exclusive rights.

What we need to establish is:

What legally protectable or proprietary assets underpin Wellbeing's CFT proposition?

Ask for the IP Schedule

For any prospective investor, there is a relatively straightforward way of addressing this.

Ask Wellbeing's legal and finance team for the intellectual-property schedule included in its due-diligence materials.

If the organisation's value depends materially upon proprietary biotechnology, investors would reasonably want to understand:

Which patents are relevant to CFT?

Who owns them?

Which applications remain pending?

Which patents remain in force?

What licences exist?

Are those licences exclusive?

Which territories are covered?

Who owns the manufacturing know-how?

Who owns improvements developed by Stephen Ray or other consultants?

What happens to those rights if key personnel leave?

And importantly:

What relationship does any of this have to Lydac Neuroscience?

These are not accusations.

They are elementary biotechnology due diligence.

Wellbeing's Research Library Doesn't Answer the Ownership Question

Wellbeing has built an extensive public research library.

At present, it lists 235 papers across 11 fields of research, covering extracellular vesicle biology, secretome science, manufacturing, ageing, neurological research and other areas. (Wellbeing International Foundation)

That is useful for understanding the broader scientific field.

But independent academic papers are not proprietary intellectual property belonging to Wellbeing.

Wellbeing itself correctly explains that these are independent scientific works gathered for educational reference. (Wellbeing International Foundation)

That distinction matters.

A large evidence library demonstrates the existence of a scientific field.

It does not establish ownership of the commercial technology being offered within that field.

Perhaps There Is No Missing Asset

We must also seriously consider the possibility that the title of this chapter ultimately proves wrong.

Perhaps there is no missing asset.

Perhaps EP2240189B1 simply became irrelevant.

Perhaps Wellbeing's present process is sufficiently different that the old patent has no meaningful relationship to it.

Perhaps later discoveries created a new manufacturing process.

Perhaps the real commercial advantage lies entirely in confidential laboratory protocols.

Perhaps Wellbeing holds licences we simply cannot see publicly.

Perhaps another entity owns the IP and Wellbeing legitimately operates under agreement.

Any of those explanations could resolve this.

But until we identify which one applies, uncertainty remains.

Wellbeing Could Answer This Very Easily

The organisation could clarify:

whether CFT derives from Ray's Lydac-era microvesicle technology;

whether the Lydac patent family has any relevance to CFT today;

which entity owns the intellectual property underlying CFT;

whether Wellbeing owns or licenses patents;

whether it acquired any intellectual property from Lydac;

and whether its principal proprietary protection instead lies in trade secrets, manufacturing protocols or later know-how.

A clear answer would materially advance this investigation.

What We Are Not Saying

This distinction is essential.

I am not alleging that Wellbeing is using intellectual property it does not own.

I am not alleging that Andrew Chancellor removed intellectual property from Lydac.

I am not alleging that Stephen Ray improperly transferred technology.

I am not alleging that Lydac's creditors were deprived of an asset.

And I am not claiming that EP2240189B1 covers the CFT treatment being offered today.

We do not currently have evidence sufficient to make those claims.

What we do have is enough evidence to ask a serious question about provenance and ownership.

And when private investors are being invited to finance the continuing development of the organisation, that question becomes particularly important.

What We Can Now Establish

We can document that Stephen Ray is the named inventor on an international microvesicle patent family originally assigned to Lydac Neuroscience. (Google Patents)

We can document that the patent describes autologous microvesicles and potential therapeutic applications. (Google Patents)

We can document that Wellbeing's present CFT description includes autologous extracellular vesicles. (Wellbeing International Foundation)

We can document that Wellbeing itself describes Ray as its Senior Scientific Consultant with more than thirty years' experience in cell-therapy research. (Wellbeing International Foundation)

We can document that Wellbeing says Ray was involved in an autologous extracellular-vesicle treatment programme by November 2017. (Wellbeing International Foundation)

And we can document that Wellbeing is currently raising private capital to support research and expansion. (Wellbeing International Foundation)

What we cannot yet document is the complete legal chain connecting those pieces.

That is the gap.

Conclusion: Show the Chain

This investigation began with people.

Then it became about science.

Then patents.

Then companies.

Then insolvency.

Now those threads are beginning to converge.

Stephen Ray developed microvesicle technology.

Patent records associate that technology with Lydac Neuroscience.

Andrew Chancellor subsequently became a director of Lydac.

Wellbeing's own account says Ray was involved with autologous extracellular-vesicle treatment by 2017.

Lydac collapsed in 2018.

Today, Ray and Chancellor are both associated with Wellbeing.

Wellbeing promotes an autologous Cell-Free Therapy containing extracellular vesicles.

And Wellbeing is raising private investment.

None of that proves wrongdoing.

But it creates a question that should have a documentary answer.

Where is the chain?

If the old technology is irrelevant, demonstrate the difference.

If new technology replaced it, identify when that happened.

If Wellbeing acquired the rights, show the ownership history.

If it licenses them, explain the licensing structure.

If the real proprietary asset is confidential know-how rather than patents, explain what entity owns that know-how.

Because investors should not have to infer ownership from biographies.

Patients should not have to infer scientific provenance from marketing.

And an organisation presenting decades of scientific development should be able to explain how that science became the technology it commercialises today.

The question is no longer simply:

Where did Stephen Ray's science come from?

We have begun answering that.

The question now is:

Who owns it today?

Next: Chapter Ten — Following the Patent Trail: From Lydac to Wellbeing

In Chapter Ten, we move from scientific similarity to legal ownership. We follow the microvesicle patent family across jurisdictions, examine assignments and legal status, and search for later patents or successor technology. If the rights moved from Lydac, there should be a trail. If they didn't, we need to understand what intellectual property actually protects Wellbeing's Cell-Free Therapy today.